Relapse and long-acting injectable risperidone: A 1-year mirror image study with a national claims database in Taiwan

Value in Health

Volumn 12, Issue SUPPL. 3, 2009, Pages

  Su, Kuan Pin ^a,b   Chang, Hui Chih ^b,c   Tsai, Shih Jen ^d   Yen, Feng Chang ^e   Tang, Chao Hsiun ^c,f  

^a CHINA MEDICAL UNIVERSITY   (Taiwan)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^d NATIONAL YANG MING UNIVERSITY   (Taiwan)

^e CHENG HSIN REHABILITATION MEDICAL CENTER   (Taiwan)

^f TAIPEI MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

National Health Insurance; Relapse; Risperidone long acting injection; Schizophrenia; Taiwan

Indexed keywords

LONG ACTING DRUG; RISPERIDONE;

ADULT; AGED; ARTICLE; EMERGENCY WARD; HEALTH CARE UTILIZATION; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; INJECTION; LENGTH OF STAY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RELAPSE; SCHIZOPHRENIA; TAIWAN;

EID: 72149107845     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1111/j.1524-4733.2009.00643.x     Document Type: Article

References (24)

1. Knapp M. Schizophrenia costs and treatment cost-effectiveness. Acta Psychiatr Scand 2000 102 : S15 18.
2. Altamura AC, Bobo WV, Meltzer HY. Factors affecting outcome in schizophrenia and their relevance for psychopharmacological treatment. Int Clin Psychopharmacol 2007 22 : 249 267.
3. Shepherd M, Watt D, Falloon I, Smeeton N. The natural history of schizophrenia: a five-year follow-up study of outcome and prediction in a representative sample of schizophrenics. Psychol Med Monogr Suppl 1989 15 : 1 46.
4. Wyatt RJ. Early intervention for schizophrenia: can the course of the illness be altered? Biol Psychiatry 1995 38 : 1 3.
5. Meisenzahl EM, Koutsouleris N, Bottlender R, et al. Structural brain alterations at different stages of schizophrenia: a voxel-based morphometric study. Schizophr Res 2008 104 : 44 60.
6. Cramer JA, Rosenheck R. Compliance with medication regimens for mental and physical disorders. Psychiatr Serv 1998 49 : 196 201.
7. Dolder CR, Lacro JP, Dunn LB, Jeste DV. Antipsychotic medication adherence: is there a difference between typical and atypical agents? Am J Psychiatry 2002 159 : 103 108.
8. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005 353 : 1209 1223.
9. Davis JM, Chen N. Choice of maintenance medication for schizophrenia. J Clin Psychiatry 2003 64 (Suppl. S1624 33.
10. Davis JM, Kane JM, Marder SR, et al. Dose response of prophylactic antipsychotics. J Clin Psychiatry 1993 54 (Suppl. S24 30.
11. Schooler NR. Relapse and rehospitalization: comparing oral and depot antipsychotics. J Clin Psychiatry 2003 64 (Suppl. S1614 17.
12. Kane JM. Strategies for improving compliance in treatment of schizophrenia by using a long-acting formulation of an antipsychotic: clinical studies. J Clin Psychiatry 2003 64 (Suppl. S1634 40.
13. Denham J, Adamson L. The contribution of fluphenazine enanthate and decanoate in the prevention of readmission of schizophrenic patients. Acta Psychiatr Scand 1971 47 : 420 430.
14. Freedman R. Schizophrenia. N Engl J Med 2003 349 : 1738 1749.
15. Mueser KT, McGurk SR. Schizophrenia. Lancet 2004 363 : 2063 2072.
16. Schultz SK, Andreasen NC. Schizophrenia. Lancet 1999 353 : 1425 1430.
17. Heeg B, Buskens E, Botteman M, et al. The cost-effectiveness of atypicals in the UK. Value Health 2008 11 : 1007 1021.
18. Lecomte P, De HM, van DM, et al. A 1-year cost-effectiveness model for the treatment of chronic schizophrenia with acute exacerbations in Belgium. Value Health 2000 3 : 1 11.
19. Niaz OS, Haddad PM. Thirty-five months experience of risperidone long-acting injection in a UK psychiatric service including a mirror-image analysis of in-patient care. Acta Psychiatr Scand 2007 116 : 36 46.
20. Chang HC, Tang CH, Tsai SJ, et al. Long-acting injectable risperidone and hospital readmission: a mirror-image study using a national claim-based database in Taiwan. J Clin Psychiatry 2009 70 : 141.
21. Marriott P, Hiep A. A mirror image out-patient study at a depot phenothiazine clinic. Aust N Z J Psychiatry 1976 10 : 163 167.
22. Polonowita A, James NM. Fluphenazine decanoate maintenance in schizophrenia: a retrospective study. N Z Med J 1976 83 : 316 318.
23. Lane HY, Chiu WC, Chou JC, et al. Risperidone in acutely exacerbated schizophrenia: dosing strategies and plasma levels. J Clin Psychiatry 2000 61 : 209 214.
24. Burns T. Hospitalisation as an outcome measure in schizophrenia. Br J Psychiatry 2007 191 (Suppl. S37 41.